We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Triad Pharmaceuticals Adopts new Name of Arisaph Pharmaceuticals
News

Triad Pharmaceuticals Adopts new Name of Arisaph Pharmaceuticals

Triad Pharmaceuticals Adopts new Name of Arisaph Pharmaceuticals
News

Triad Pharmaceuticals Adopts new Name of Arisaph Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Triad Pharmaceuticals Adopts new Name of Arisaph Pharmaceuticals "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Triad Pharmaceuticals, Inc. has announced that the Company is changing its name to Arisaph Pharmaceuticals, effective immediately.

The Arisaph name establishes the Company's unique identity. Moreover, Arisaph is derived from the ancient Greek language and reflects the Company's goal of creating best-in-class or smart medicines to improve human heath.

"The uniqueness of the Arisaph name symbolizes our differentiated approach to rational drug design, in which we leverage our strong medicinal chemistry expertise and our proprietary drug discovery technology platforms to create 'ultra-smart' medicines," said Christopher P. Kiritsy, President and Chief Executive Officer, of Arisaph Pharmaceuticals.

"In our ongoing drug discovery programs, we have made significant progress in fulfilling our product development mission by designing three novel candidate drugs for cardiovascular disorders as well as two differentiated lead candidates for the treatment of type II diabetes."

Advertisement